Insurance Barriers Limit Children’s Access to Biologics for Asthma
-
By
-
Debbie Bunch
-
November 16, 2026
Objective:
To examine insurance approval, denial, and treatment-start delays for biologic prescriptions issued to children by allergists.
Approach:
- Study sample: Investigators reviewed 326 biologic prescriptions for pediatric patients from 2018 through 2026. Mean age was 11 years; approximately half were male.
- Medications: Omalizumab accounted for 55.8% of prescriptions and dupilumab for 26%.
Key Findings:
- Insurance approval was required before dispensing for nearly all prescriptions.
- Approximately 40% of prescriptions were ultimately denied.
- Common denial reasons included requirements to try another medication first or failure to meet insurer criteria.
- For children who received treatment, the time from prescription to initiation generally exceeded one month; some families waited longer.
Interpretation:
Study co-author Aarti Pandya, MD, said delays may put children with uncontrolled asthma or allergies at risk for serious health problems. The authors called for discussion of ways to streamline and accelerate approvals.
Limitations:
- The study was conducted at a single academic medical center, which may limit how well the findings apply to other settings.
- The review included prescriptions from 2018 through 2026, so changes in insurance policies and biologic availability over time may have affected the results.
- The study examined prescription approval and treatment timing, but did not assess the clinical outcomes of delays or denials.
Conclusion:
Insurance barriers can delay or prevent children from receiving biologic treatment prescribed by their allergists. Nearly all prescriptions required prior insurance approval, and approximately 40% were ultimately denied, often because insurers required patients to try another medication first or determined they did not meet coverage criteria. For children who started treatment, initiation generally took more than a month after the prescription was issued. The authors called for efforts to streamline and accelerate the approval process so children can start treatment sooner.
Sources:
Based on findings from:
Insurance Companies Make It Difficult for Kids with Asthma to Get Biologics
Debbie Bunch. American Association For Respiratory Care, 2026.
https://rccentral.aarc.org/insurance-barriers-biologics-children-severe-asthma/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.